Beam Therapeutics Inc. Operating Expenses
Beam Therapeutics Inc. (BEAM) reported Operating Expenses of $127.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- Beam Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $127.04M, a 1.22% decline year-over-year.
- Beam Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $138.95M, a 9.62% increase year-over-year.
- Beam Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $131.55M, a 1.11% increase year-over-year.
- Beam Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $136.51M, a 13.03% increase year-over-year.
- Beam Therapeutics Inc. operating expenses for fiscal 2025 was $523.44M, a 9.26% increase from fiscal 2024.
- Beam Therapeutics Inc. operating expenses for fiscal 2024 was $479.09M, a 13.55% decline from fiscal 2023.
- Beam Therapeutics Inc. operating expenses for fiscal 2023 was $554.19M, a 38.76% increase from fiscal 2022.
- Beam Therapeutics Inc. operating expenses for fiscal 2022 was $399.40M, a 10.11% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.04M 10-Q · filed 2026-08-04 | $266.00M 10-Q · filed 2026-08-04 | $397.55M derived: sum of 3 quarters · filed 2026-08-04 | $534.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $138.95M 10-Q · filed 2026-05-07 | $270.51M derived: sum of 2 quarters · filed 2026-05-07 | $407.02M derived: sum of 3 quarters · filed 2026-05-07 | $535.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $131.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $268.06M derived: sum of 2 quarters · filed 2026-02-24 | $396.68M derived: sum of 3 quarters · filed 2026-08-04 | $523.44M 10-K · filed 2026-02-24 |
| 2025-09-30 | $136.51M 10-Q · filed 2025-11-04 | $265.13M derived: sum of 2 quarters · filed 2026-08-04 | $391.88M 10-Q · filed 2025-11-04 | $521.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $128.62M 10-Q · filed 2026-08-04 | $255.37M 10-Q · filed 2026-08-04 | $385.48M derived: sum of 3 quarters · filed 2026-08-04 | $506.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $126.76M 10-Q · filed 2026-05-07 | $256.86M derived: sum of 2 quarters · filed 2026-05-07 | $377.63M derived: sum of 3 quarters · filed 2026-05-07 | $494.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $130.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $250.88M derived: sum of 2 quarters · filed 2026-02-24 | $367.54M derived: sum of 3 quarters · filed 2026-02-24 | $479.09M 10-K · filed 2026-02-24 |
| 2024-09-30 | $120.77M 10-Q · filed 2025-11-04 | $237.44M derived: sum of 2 quarters · filed 2025-11-04 | $348.98M 10-Q · filed 2025-11-04 | $532.32M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $116.67M 10-Q · filed 2025-08-05 | $228.21M 10-Q · filed 2025-08-05 | $411.54M derived: sum of 3 quarters · filed 2026-02-24 | $537.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $111.54M 10-Q · filed 2025-05-06 | $294.88M derived: sum of 2 quarters · filed 2026-02-24 | $420.34M derived: sum of 3 quarters · filed 2026-02-24 | $542.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $183.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $308.79M derived: sum of 2 quarters · filed 2026-02-24 | $431.06M derived: sum of 3 quarters · filed 2026-02-24 | $554.19M 10-K · filed 2026-02-24 |
| 2023-09-30 | $125.46M 10-Q · filed 2024-11-05 | $247.72M derived: sum of 2 quarters · filed 2024-11-05 | $370.86M 10-Q · filed 2024-11-05 | $479.88M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $122.26M 10-Q · filed 2024-08-06 | $245.40M 10-Q · filed 2024-08-06 | $354.42M derived: sum of 3 quarters · filed 2025-02-25 | $461.52M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $123.14M 10-Q · filed 2024-05-07 | $232.16M derived: sum of 2 quarters · filed 2025-02-25 | $339.26M derived: sum of 3 quarters · filed 2025-02-25 | $437.88M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $109.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $216.12M derived: sum of 2 quarters · filed 2025-02-25 | $314.74M derived: sum of 3 quarters · filed 2025-02-25 | $399.40M 10-K · filed 2025-02-25 |
| 2022-09-30 | $107.10M 10-Q · filed 2023-11-08 | $205.72M derived: sum of 2 quarters · filed 2023-11-08 | $290.38M 10-Q · filed 2023-11-08 | $404.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $98.62M 10-Q · filed 2023-08-08 | $183.28M 10-Q · filed 2023-08-08 | $297.83M derived: sum of 3 quarters · filed 2024-02-27 | $368.23M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $84.66M 10-Q · filed 2023-05-10 | $199.21M derived: sum of 2 quarters · filed 2024-02-27 | $269.61M derived: sum of 3 quarters · filed 2024-02-27 | $328.59M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $114.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $184.95M derived: sum of 2 quarters · filed 2024-02-27 | $243.93M derived: sum of 3 quarters · filed 2024-02-27 | $444.31M 10-K · filed 2024-02-27 |
| 2021-09-30 | $70.40M 10-Q · filed 2022-11-07 | $129.38M derived: sum of 2 quarters · filed 2022-11-07 | $329.76M 10-Q · filed 2022-11-07 | $370.56M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $58.98M 10-Q · filed 2022-08-09 | $259.36M 10-Q · filed 2022-08-09 | $300.16M derived: sum of 3 quarters · filed 2023-02-28 | $337.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $200.38M 10-Q · filed 2022-05-09 | $241.18M derived: sum of 2 quarters · filed 2023-02-28 | $278.51M derived: sum of 3 quarters · filed 2023-02-28 | $304.80M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $40.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $78.13M derived: sum of 2 quarters · filed 2023-02-28 | $104.42M derived: sum of 3 quarters · filed 2023-02-28 | $132.78M 10-K · filed 2023-02-28 |
| 2020-09-30 | $37.33M 10-Q · filed 2021-11-08 | $63.62M derived: sum of 2 quarters · filed 2021-11-08 | $91.98M 10-Q · filed 2021-11-08 | $118.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $26.29M 10-Q · filed 2021-08-10 | $54.65M 10-Q · filed 2021-08-10 | $81.03M derived: sum of 3 quarters · filed 2022-02-28 | $99.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $28.36M 10-Q · filed 2021-05-11 | $54.74M derived: sum of 2 quarters · filed 2022-02-28 | $72.77M derived: sum of 3 quarters · filed 2022-02-28 | $90.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $26.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $44.41M derived: sum of 2 quarters · filed 2022-02-28 | $62.06M derived: sum of 3 quarters · filed 2022-02-28 | $75.17M 10-K · filed 2022-02-28 |
| 2019-09-30 | $18.03M 10-Q · filed 2020-11-10 | $35.69M derived: sum of 2 quarters · filed 2020-11-10 | $48.80M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $17.66M 10-Q · filed 2020-08-12 | $30.77M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $13.11M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |